Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope

International Journal of Diabetes in Developing Countries

Volumn 29, Issue 3, 2009, Pages 110-117

  Rahman, Sayeeda ^a   Ismail, Aziz ^b   Rahman, Abdul Rashid ^c  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b SCHOOL OF HEALTH SCIENCES   (Malaysia)

^c CYBERJAYA UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (Malaysia)

Author keywords

Diabetic vasculopathy; Ramipril; Rosiglitazone

Indexed keywords

EID: 70349213612     PISSN: 09733930     EISSN: 19983832     Source Type: Journal    
DOI: 10.4103/0973-3930.54287     Document Type: Review

References (56)

1. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, et al. The burden of mortality att ributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005;28:2130-.
2. IDF (2007). Fact Sheet Diabetes and cardiovascular disease (CVD). Available from: http://www.idf.org/home/index.cfm-node=1158. [cited in 2007].
3. Cooper ME, Bonnet F, Oldfi eld M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: An overview. Am J Hypertens 2001;14:475-486
4. Rahman S, Rahman T, Ismail AA, Rahman AR. Diabetes-associated macrovasculopathy: Pathophysiology and pathogenesis. Diabetes, Obesity and Metabolism 2007;9:767-780
5. Nicolaides E, Jones CJH. Type 2 diabetes - implications for macrovascular mechanics and disease. Br J Diabetes Vasc Dis 2002;2:9-12
6. Cooper ME, Gilbert RE, Epstein M. Pathophysiology of diabetic nephropathy. Metabolism 1998;47:3-6.
7. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005.
8. Scheen AJ. Treatment of type 2 diabetes. Acta Clin Belg 2003;58:318-324
9. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28:S4-S36.
10. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-2803.
11. Heart Outcomes Prevention Evaluation Study Investigators. Eff ects of an angiotensin converting enzyme inhibitor, Ramipril on death from cardiovascular causes, myocardial infarction, and stroke in high risk patients. N Engl J Med 2000;342:145-153
12. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Erdmann E, Massi-Benedett i M et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289
13. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006;368:1096-1105
14. The DREAM Trial Investigators. Effect of Ramipril on the Incidence of Diabetes. N Engl J Med 2006;355:1-12.
15. Raynolds K, Goldberg RB. Thiazolidinediones: beyond glycemic control. Treatments Endocrinol 2006;5:25-36.
16. Hughes K, Aw TC, Kuperan P, Choo M. Central obesity, insulin resistance, syndrome X, lipoprotein(a), and cardiovascular risk in Indians, Malays, and Chinese in Singapore. J Epidemiol Community Health 1997;51:394-399
17. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003;91:H30-7.
18. The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: The DREAM trial Diabetologia 2004;47:1519-1527
19. Carlsson PO, Barne C, Jansson L. Angiotensin II and the endocrine pancreas. Diabetologia 1998;41:127-133
20. Vourinen-Markkola H, Yki-Jarnen H. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism 1995;44:85-89
21. Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ. ACE inhibition and glucose transport in insulin muscle: roles of bradykinin and nitric oxide. Am J Physiol 1999;277:R332-6.
22. Torlone E, Rambott i AM, Perriello G, Bott a G, Santeusanio F, Brunett i P, et al. ACE inhibition increases hepatic and extrahepatic sensitivity to insulin patients with type 2 (non-insulin dependent) diabetes mellitus and arterial hypertension. Diabetologia 1991;34:119-125
23. Nolan JJ, Jones NP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides eff ective glycaemic control in patients with type 2 diabetes. Diabet Med 2000;17:287-294
24. Patel J, Miller E, Patwardhan R. Rosiglitazone (BRL49653) monotherapy has signifi cant glucose lowering effect in type 2 diabetic patients. Diabetes 1998;47:A17.
25. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed M. Rosiglitazone short-term monotherapy lowers fasting and postprandial glucose in patients with Type II diabetes. Diabetologia 2000;43:278-284
26. Phillips LS, Grunberger G, Miller E, Patwardham R, Rappaport EB, Salzman A. Once- and twice daily doing of rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;124:308-315
27. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI for the rosiglitazone clinical trials study group. Rosiglitazone monotherapy is eff ective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-288
28. Charbonnel B, Lonnqvist F, Jones NP, Patwardhan R. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose aft er 1 year of treatment in type 2 diabetic patients. Diabetes 1999;48:All4.
29. Hanefeld M, Patwardhan R, Jones NP for the Rosiglitazone Clinical Trial Group. A one-year study comparing the effi cacy and safely of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis 2007;17:13-23.
30. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471 (Pubitemid 46919772)
31. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al. Rosiglitazone evaluated for cardiovascular outcomes: An interim analysis. N Engl J Med 2007;357:28-38.
32. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-616 (Pubitemid 29087980)
33. ALLHAT Collaborative Research Group. Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997
34. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
35. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-2572
36. Pfeff er MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003;362:759-766 (Pubitemid 37093915)
37. Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients: North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995;8:876-883
38. Nielsen FS, Sato A, Ali S, Tarnow L, Smidt UM, Kastrup J, et al. Benefi cial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients. Diabetes Care 1998;21:804-809
39. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000;355: 253-259
40. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A Serial Intravascular Ultrasound Study. J Am Coll Cardiol 2000;36:1529-1535 (Pubitemid 30825986)
41. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Morioka S, et al. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 2002;89:318-322
42. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory eff ect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83: 1818-1820
43. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory eff ect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-3456
44. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, et al. Antiatherogenic Eff ect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic Effect. Diabetes Care 2003;26:2493-2499
45. Langenfeld MR, Forst T, Hohberg C, Kann P, L?bben G, Konrad T, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes: Results from a controlled randomized study. Circulation 2005;111:2525-2531
46. Watanabe I, Tani S, Anazawa T, Kushiro T, Kanmatsuse K. Eff ect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. Diabetes Res Clin Pract 2005;68:104-110
47. Kim SG, Ryu OH, Kim HY, Lee KW, Seo JA, Kim NH, et al. Eff ect of rosiglitazone on plasma adiponectin level and arterial stiff ness in subjects with prediabetes or non-diabetic metabolic syndrome. Eur J Endocrin 2006;154:433-440
48. Shargorodsky M, Wainstein J, Gavish D, Leibovitz E, Matas Z, Zimlichman R. Treatment With Rosiglitazone Reduces Hyperinsulinemia and Improves Arterial Elasticity in Patients With Type 2 Diabetes Mellitus. Am J Hyperten 2003;16:617-622
49. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In Type 2 diabetes rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004;27:484-490
50. Hetzel J, Balletshofer B, Ritt ig K, Walcher D, Kratzer W, Hombach V, et al. Rapid Eff ects of Rosiglitazone Treatment on Endothelial Function and Inflammatory Biomarkers. Arterioscler Thromb Vasc Biol 2005;25:1804-1809
51. Rahman S, Ismail AAS, Ismail SB, Naing NN, Rahman ARA. Eff ect of Rosiglitazone and Ramipril on Preclinical Vasculopathy in Newly Diagnosed, Untreated T2DM and IGT Patients: One-year Randomised, Double-blind and Placebo-controlled Study. Eur J Clin Pharmacol 2007;63:733-741
52. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-2069
53. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, et al. Eff ects of ramipril and vitamin E on atherosclerosis: The study to evaluate carotid untrasound changes in patients with ramipril and vitamin E (SECURE). Circulation 2001;103:919-925
54. Secree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance: Prevalence and projections. In: Allgot B, Gan D, King H, et al, editors. Diabetes atlas, 2nd ed. Brussels: International Diabetes Federation; 2003. p. 17-71.
55. IDF (2001). Diabetes and cardiovascular disease: A time to act. Brussels. International Diabetes Federation, 2001.
56. Simpson RW, Shaw JE, Zimmet PZ. The prevention of type 2 diabetes lifestyle change or pharmacotherapy? A challenge for the 21st century. Diabetes Res Clin Pract 2003;59:165-180